ERBB2 and breast cancer: Consistent with our hypothesis, the dual drug inhibition of HER2 and STEAP4 by the combinational treatment of Lapatinib with the DFP significantly decreased cell proliferation in the HER2+ BC cell lines (HCC-1954, SKBR3, BT474) than either drug alone, suggesting a new pharmacological treatment scheme for HER2+ BC.